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Desaturase and elongase 
A B S T R A C T   
Introduction: Fatty acids are essential nutrients for the fetus and are supplied by the mother through the placenta. 
Desaturase and elongase enzymes play an important role in modulating the fatty acid composition of body tis-
sues. We aimed to compare the fatty acid profile and the estimated desaturase and elongase activities in the 
placenta of appropriate (AGA) versus small-for-gestational-age (SGA), and to determine their relationship with 
the offspring size at birth. 
Methods: The placental fatty acid profile was analyzed by gas chromatography in 84 infants (45 AGA and 30 SGA) 
from a prenatal cohort study. The estimated desaturase and elongase activities were calculated from product- 
precursor fatty acid ratios. Results were associated with maternal (age, body mass index and weight gain dur-
ing gestation) and neonatal (gestational age, sex, birth weight and birth length) parameters. 
Results: Differences in placental fatty acid composition between AGA and SGA infants rather than correlations 
thereof with neonatal parameters were observed. Placentas from SGA infants contained lower levels of omega-3 
(ALA, EPA, DPA, and DHA) and high omega-6/omega-3 ratios (AA/DHA and LA/ALA), as well as low elongase 
(Elovl5) and high desaturase (D9Dn7 and D5Dn6) activity as compared to AGA infants (all p < 0.0001). 
Discussion: Placentas of AGA and SGA infants differed in fatty acids profile as well as in estimated desaturase and 
elongase activities. A striking feature of SGA placentas was the low availability of omega-3. Hence, omega-3 fatty 
acid status deserves further attention, as a potential target of prenatal interventions.   
1. Introduction 
Between 5-10% of infants born at term are small for gestational age 
(SGA). The SGA condition is associated with a higher risk of adverse 
outcomes during pregnancy, labor, and the neonatal period [1,2], which 
contribute to neurodevelopmental and metabolic disorders in these 
subjects [3,4]. Approximately 90% of SGA infants experience sponta-
neous postnatal catch-up growth, which, when rapid and pronounced, 
can predispose to insulin resistance, accumulation of central adiposity, 
early and rapidly evolving puberty, and increased risks of developing 
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type 2 diabetes and cardiovascular disease later in life [5–7]. Most cases 
of low birth weight and/or length result from defective placental func-
tion and failure to meet the nutritional requirements of the fetus to 
support adequate growth [8]. 
During the last trimester of pregnancy, fetal requirements for long- 
chain polyunsaturated fatty acids (LC-PUFA) are high [9]. LC-PUFA 
are important constituents of cell membranes and provide the pre-
cursors for eicosanoid production [9], which are needed for the normal 
development of the nervous and vascular systems [10]. There are two 
types of essential PUFAs, omega-6 (n6) and omega-3 (n3). Omega-6 fatty 
acids are represented by linoleic acid (18:2n6, LA) and omega-3 fatty 
acids by alpha-linolenic acid (18:3n3, ALA). Both essential fatty acids 
are metabolized to longer-chain fatty acids of 20 and 22 carbon atoms. 
LA is metabolized to arachidonic acid (20:4n6, AA) and ALA is metab-
olized to eicosapentaenoic acid (20:5n3, EPA) and docosahexaenoic acid 
(22:6n3, DHA) [11]. Since the fetus cannot efficiently synthesize these 
fatty acids [12], fetal essential fatty acids (EFAs) and their long-chain 
derivatives are supplied by the mother through the placenta [13]. 
Several authors have suggested that both maternal and umbilical cord 
PUFAs influence body adiposity and cardiometabolic health of the 
offspring [14–17]. 
Besides dietary intake of fatty acids, the activity of the desaturase 
and elongase enzymes play an important role in modulating the fatty 
acid composition of body tissues [18]. Although direct measurement of 
the enzyme activity is difficult, it can be estimated from the 
product-precursor ratio [19,20]. The elongases of very long-chain fatty 
acid (ELOVL) are essential in the biosynthesis of fatty acids longer than 
14 carbons [21]. The delta-9-desaturases (D9D) catalyze the desatura-
tion of 12–19 carbon saturated fatty acids (SFA) to monounsaturated 
fatty acids (MUFA) and both the delta-6-desaturase (D6D) and 
delta-5-desaturase (D5D), catalyze the rate-limiting steps in the con-
version of the n6 and n3 PUFA (LA and ALA) to their long-chain me-
tabolites (AA and EPA), respectively [22]. The activity of these enzymes 
is regulated by nutrient and hormone status and has shown to be asso-
ciated with obesity and cardiometabolic risk factors in adult tissues 
[23–25]. 
Altered composition of circulating fatty acids has been reported in 
mothers and infants with growth restriction [26–30], including a lower 
fetal-to-maternal proportion of the LC-PUFA (AA and DHA) and reduced 
conversion ratios from their derivatives (LA and ALA). In the placenta, a 
similar fatty acid profile was observed between normal and restricted 
groups, but the proportion of fatty acids of the linoleic acid series (n6) 
and the conversion ratio of DHA from its precursor LA (n3) was signif-
icantly lower in the restricted placenta compared to the normal placenta 
[28,31]. Several studies in premature infants showed that smaller size at 
birth was related to lower EFA concentrations in the infant [32–35]. 
Knowledge about the fatty acid composition and the activity of the 
desaturase and elongase enzymes in placentas from SGA term neonates 
is scarce. We hypothesize that the placental fatty acid profile and the 
estimated enzymatic activity will be different between SGA and AGA 
term neonates, and will associate with offspring size at birth. 
The present study, therefore, aims to compare the fatty acid profile 
and the estimated desaturase and elongase activities from placentas of 
AGA versus SGA infants at term birth, and to determine their relation-
ship with the offspring size at birth. 
2. Material and methods 
2.1. Study population and ethics 
The study cohort consisted of 84 mother-newborn pairs recruited at 
the Hospital Dr. Josep Trueta of Girona and the Hospital Sant Joan de 
Déu of Barcelona (Spain) within a prenatal cohort study of mothers and 
infants. Fifty-four infants were born AGA (21 girls, 33 boys) and 30 SGA 
(14 girls, 16 boys). The inclusion criteria were: (i) infants born at term 
(37–42 weeks) from singleton pregnancies, (ii) placentas collected at 
delivery, and (iii) informed written consent obtained. The exclusion 
criteria were: (i) maternal disease (hypertension, preeclampsia, gesta-
tional diabetes, or preexisting type 1 and type 2 diabetes mellitus), 
alcohol abuse or drug addiction, and (ii) fetal malformations or com-
plications at birth. 
The study was approved by the Institutional Review Board of the 
Hospital Dr. Josep Trueta of Girona and the Hospital Sant Joan de Déu at 
the University of Barcelona. Written informed consent was obtained 
before delivery. 
2.2. Clinical assessments 
Maternal age at conception, height, pregestational weight, and 
gestational weight gain, were retrieved from medical records. Body- 
mass index (BMI) was calculated as weight/height squared (kg/m2). 
Weight and length of the newborns were measured after delivery and 
are shown here as standard deviation scores (Z-score) adjusting for 
gestational age and sex according to regional normative data. Gesta-
tional age was calculated from last menses and was confirmed by ul-
trasound when needed. Children with birth weight Z-score ≤ − 2 were 
classified as SGA and children with − 0.5 ≤ birth weight Z-score ≤ +0.5 
were classified as AGA. 
The placentas were collected after childbirth in the delivery room 
and processed immediately. Placentas were weighed and three 1 cm3 
cuboidal sections were collected from the maternal side of the placenta 
after removing the decidua. Placental samples were washed 3 times with 
physiological saline to remove all maternal blood and immediately were 
frozen at − 80 ◦C until analyzed. The personnel were wearing facial 
masks and sterile gloves and were also using a sterile scalpel and 
instruments. 
2.3. Placental fatty acid profile and estimated indices 
Percentages of total fatty acids from placental lipids (including 
glycerolipids, phospholipids, sphingolipids, sterol lipids and free fatty 
acids) were analyzed as fatty acid methyl ester derivatives (FAMEs) by 
gas chromatography (GC) as previously described [36]. Lipids from 
placental samples (containing 500 mg of tissue) were extracted with 
chloroform/methanol (2:1, v/v) in the presence of 0.01% butylated 
hydroxytoluene. The chloroform phase was evaporated under nitrogen, 
and the fatty acids were trans-esterified by incubation in 2 ml of 5% 
methanolic HCl at 75 ◦C for 90 min. The resulting fatty acid methyl 
esters were extracted by adding 2 ml of n-pentane and 1 ml of saturated 
NaCl solution. The n-pentane phase was separated, evaporated under 
nitrogen and redissolved in 80 μl of carbon disulphide. A total amount of 
4 μl was used for GC analysis. Separation was performed with a DBWAX 
capillary column (30 m × 0.25 mm x 0.20 μm) in a GC System 7890A 
with a Series Injector 7683B and a FID detector (Agilent Technologies, 
Barcelona, Spain). Identification of fatty acid methyl esters was made by 
comparison with authentic standards (Larodan Fine Chemicals, Malmö, 
Sweden). Results are expressed as mol%. 
The following fatty acyl indices were calculated: saturated fatty acids 
(SFA); monounsaturated fatty acids (MUFA); polyunsaturated fatty acids 
(PUFA) from n3 and n6 series (PUFAn3 and PUFAn6, respectively); and 
the following ratios were obtained: PUFAn6/PUFAn3, LA(n6)/ALA(n3), 
AA(n6)/DHA(n3), LA + AA n6 score, ALA + DHA n3 score, AA(n6)/LA 
(n6) and DHA(n3)/ALA(n3). 
Desaturase and elongase activities were estimated from specific 
product-precursor fatty acid ratios: D9Dn7 = 16:1n9/16:0; D9Dn9 =
18:1n9/18:0; D6Dn3 = 18:4n3/18:3n3, D5Dn6 = 20:4n6/20:3n6; 
D4Dn6 = 22:5n6/22:4n6; D4Dn3 = 22:6n3/22:5n3; Elovl3 = 20:1n9/ 
18:1n9; Elovl6 = 18:0/16:0; Elovl1a = 20:0/18:0; Elovl1b = 22:0/20:0; 
Elovl1c = 24:0/22:0; Elovl5 = 20:2n6/18:2n6; Elovl2n6 = 22:4n-6/ 
20:4n-6 and Elovl2n3 = 22:5n-3/20:5n-3. 
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2.4. Statistical analysis 
Descriptive characteristics are shown as mean ± SEM. Statistical 
analyses were performed using SPSS Statistics 22.0 (SPSS, Chicago, IL). 
For variables with non-normal distribution, data were logarithmically 
transformed before analyses. Unpaired t-test was used to study differ-
ences between AGA and SGA subgroups. The level of significance was set 
at p ≤ 0.05. Bivariate correlations were done to study the associations 
between the placental fatty acid profile and offspring birth weight and 
birth length. Multiple linear regression analyses were performed to 
correct by maternal (age, BMI, gestational weight gain) and neonatal 
(gestational age and sex) confounders. 
3. Results 
3.1. Maternal and newborns’ characteristics 
Table 1 summarizes the anthropometric parameters of the mothers 
and newborns by birth weight subgroup. There were no differences 
between the groups regarding maternal age at conception, pregesta-
tional weight and BMI, gestational weight gain, and newborns’ sex. As 
expected, SGA infants at birth were smaller than AGA children, and they 
did also have smaller placentas (all p < 0.0001). 
3.2. Placental fatty acid profile 
Comparisons of placental fatty acid profiles from AGA and SGA 
subgroups are shown in Table 2. The percentage of total fatty acids 
indices was similar between both groups although there were some 
differences within individual fatty acids mainly from the omega-3 and 
omega-6 series. Placentas from SGA infants contained lower levels of 
several PUFAn3 including alpha-linolenic acid (ALA, 18:3n3), eicosa-
pentaenoic acid (EPA, 20:5n3), docosapentaenoic acid (DPA, 22:5n3) 
and docosahexaenoic acid (DHA, 22:6n3) (all p < 0.0001). The ALA +
DHA n3 score and the total PUFAn3 was also significantly lower in SGA 
than in AGA infants (p < 0.0001 and p = 0.04, respectively). On the 
other hand, higher levels of LA + AA n6 score (p = 0.04) and also of the 
different omega-6/omega-3 ratios (PUFAn6/PUFAn3, LA/ALA and AA/ 
DHA) were observed in SGA infants (all p < 0.0001). Fig. 1A shows the 
differential fatty acids among AGA and SGA expressed as SGA Z-scores 
using the AGA mean as reference. 
None of these fatty acids were associated with birth weight or length 
of the infants (not shown). However, the differences in placental fatty 
acid composition between AGA and SGA infants were maintained in 
multivariate analyses adjusted for maternal (age, BMI, gestational 
weight gain) and neonatal (gestational age and sex) characteristics. 
Table 1 
Characteristics of the studied population.   
AGA (n = 54) SGA (n = 30) P value 
Mothers 
Age (yr) 31.0 ± 0.5 30.3 ± 1.1 Ns 
Height (cm) 163.1 ± 0.7 159.5 ± 1.13 0.009 
Weight (Kg) 58.8 ± 0.7 57.33 ± 1.7 Ns 
BMI (Kg/m2) 22.1 ± 0.2 22.60 ± 0.7 Ns 
Gestational weight gain (Kg) 11.6 ± 0.3 11.5 ± 0.9 Ns 
Newborns 
Sex (%F) 40 46 Ns 
Gestational age (weeks) 39.6 ± 0.1 38.2 ± 0.2 <0.0001 
Placental weight (Kg) 0.58 ± 0.01 0.46 ± 0.01 <0.0001 
Birth weight (Kg) 3.26 ± 0.03 2.22 ± 0.05 <0.0001 
Birth weight Z-score − 0.03 ± 0.08 − 2.36 ± 0.06 <0.0001 
Birth length (cm) 49.41 ± 0.20 44.80 ± 0.38 <0.0001 
Birth length Z-score − 0.22 ± 0.12 − 2.12 ± 0.13 <0.0001 
Data are mean ± SEM. t-test was used to determine differences between groups. 
Ns, not significant. 
Table 2 







14:0 (Myristic acid) 1.81 ± 0.06 1.68 ± 0.06 Ns 










20:0 (Arachidic acid) 0.33 ± 0.01 0.32 ± 0.01 Ns 
22:0 (Behenic acid) 1.59 ± 0.12 1.39 ± 0.13 Ns 
24:0 (Lignoceric acid) 0.38 ± 0.05 0.15 ± 0.01 0.004 





16:1n7 (Palmitoleic acid) 0.49 ± 0.01 0.59 ± 0.02 0.001 
18:1n7 (Vaccenic acid) 2.03 ± 0.03 1.91 ± 0.03 0.02 





20:1n9 (Eicosenoic acid) 0.26 ± 0.01 0.28 ± 0.01 Ns 
22:1n9 (Erucic acid) 0.75 ± 0.07 0.97 ± 0.04 0.04 





18:3n3 (Alpha-linolenic acid, ALA) 0.22 ± 0.01 0.15 ± 0.01 <0.0001 
18:4n3 (Stearidonic acid) 0.84 ± 0.08 0.71 ± 0.03 Ns 
20:3n3 (Eicosatrienoic acid) 3.05 ± 0.14 3.39 ± 0.14 Ns 
20:5n3 (Eicosapentaenoic acid, EPA) 0.84 ± 0.03 0.61 ± 0.02 <0.0001 
22:5n3 (Docosapentaenoic acid, DPA) 0.23 ± 0.01 0.15 ± 0.01 <0.0001 
22:6n3 (Docosahexaenoic acid, DHA) 1.04 ± 0.07 0.61 ± 0.02 <0.0001 
Total PUFAn3 6.22 ± 0.16 5.65 ± 0.14 0.02 
18:2n6 (Linoleic acid, LA) 9.53 ± 0.20 10.18 ±
0.26 
0.04 
20:2n6 (Eicosadienoic acid) 0.11 ± 0.01 0.05 ± 0.01 <0.0001 
20:3n6 (Dihomo-gamma-linolenic acid, 
DGLA) 
0.56 ± 0.01 0.51 ± 0.02 0.04 





22:4n6 (Adrenic acid) 0.49 ± 0.02 0.30 ± 0.01 <0.0001 
22:5n6 (Osbond acid) 0.11 ± 0.07 0.11 ± 0.01 Ns 





PUFAn6/PUFAn3 3.58 ± 0.08 4.27 ± 0.11 <0.0001 
LAn6/ALAn3 44.67 ±
2.11 











ALA + DHA n3 score 1.26 ± 0.07 0.76 ± 0.02 <0.0001 
AAn6/LA n6 1.19 ± 0.04 1.26 ± 0.06 Ns 
DHAn3/ALAn3 5.27 ± 0.53 4.48 ± 0.34 Ns 






D9Dn9 0.70 ± 0.01 0.71 ± 0.02 Ns 






D4Dn6 0.24 ± 0.02 0.37 ± 0.02 <0.0001 












Elovl1b 4.52 ± 0.29 4.20 ± 0.25 Ns 






Elovl2n6 0.06 ± 0.01 0.03 ± 0.01 0.007 
Elovl2n3 0.30 ± 0.01 0.26 ± 0.02 Ns 
Data are mean ± SEM. t-test was used to determine differences between groups. 
Ns, not significant. The estimated desaturase and elongase activities were 
calculated from product-precursor fatty acid ratios. Significant differences after 
adjustment for maternal (age, BMI, gestational weight gain) and neonatal 
(gestational age and sex) characteristics are shown in bold. 
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3.3. Estimated desaturase and elongase activity 
Comparisons of the estimated desaturase and elongase activities 
from AGA and SGA subgroups are shown in Table 2. Placentas from SGA 
infants showed higher desaturase (D9Dn7, D6Dn3, D5Dn6 and D4Dn6) 
and lower elongase (Elovl1c, Elovl5, Elovl2n6) activity (all p < 0.007). 
Differential desaturase and elongase activities are shown in Fig. 1B that 
depicts the enzymatic activities of SGA as Z-scores, using the AGA results 
as reference. 
None of the estimated activities were associated with birth weight or 
length of the infants (not shown). However, the differences in placental 
desaturase and elongase activities between AGA and SGA infants were 
maintained in multivariate analyses adjusted for maternal (age, BMI, 
gestational weight gain) and neonatal (gestational age and sex) 
characteristics. 
4. Discussion 
We described, for the first time to our knowledge, the fatty acid 
profile and the estimated desaturase and elongase activities in placentas 
Fig. 1. Differential placental fatty acids (A) and estimated desaturase and elongase activities (B) in SGA infants (expressed as Z-scores using the AGA results as 
reference). Negative values indicate lower levels than AGA and positive values indicate higher levels than AGA. 
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from AGA and SGA term neonates. Placentas from SGA infants showed 
low levels of omega-3 and high omega-6/omega-3 ratio, and high 
desaturase (D9Dn7 and D5Dn6) and low elongase (Elovl5) activity 
compared to AGA infants. 
Only two studies had previously examined the impact of fetal growth 
restriction on fatty acids profile in human placenta. Percy et al. (1991) 
studied the essential fatty acids pattern in placentas from AGA preg-
nancies (n = 7) and from preterm and term SGA (n = 15), and showed a 
reduction of n-6 series (including 20:3 and 20:4) in acylglycerol and 
phosphatidylcholine fatty acids from SGA placentas [31]. Assumpçao 
et al. (2017) investigated the profile of LC-PUFA in placentas from 15 
full-term normal pregnancies (AGA) and 11 pregnancies complicated by 
intrauterine growth retardation, and showed no significant differences 
in any of the studied fatty acids; however, DHA/ALA (n3) ratio was 
significantly lower in the IUGR group [28]. Our study has been per-
formed with a higher number of subjects and all infants (both AGA and 
SGA) were born at term. 
An impaired ability of the placenta to supply derivatives of LA and 
ALA from their precursors (AA and DHA, respectively) has been 
described in infants with growth restriction, most of them being pre-
mature, compared to control subjects [26,27,31,34]. However, in our 
study with term SGA newborns, no significant differences were observed 
in the conversion ratios AA/LA (n6) and DHA/AA (n3) but rather in the 
levels of PUFAn6/PUFAn3 ratios, suggesting that the main differences 
between AGA and SGA newborns at term birth are due to an imbalance 
between omega-6 and omega-3 PUFA levels. 
Experimental studies have suggested that omega-6 and omega-3 
fatty acids participate in the regulation of lipid metabolism and sys-
temic inflammation eliciting opposing effects [37,38]. While a high 
omega-6/omega-3 ratio has been associated with a pro-inflammatory 
role and the pathogenesis of many diseases, including cardiovascular 
disease, cancer, obesity and autoimmune diseases; increased levels of 
omega-3 PUFA (a low omega-6/omega-3 ratio) has shown to exert 
anti-inflammatory effects and to protect against cardiometabolic dis-
eases [39]. On the basis of these findings, and given that the fatty acid 
composition of the placenta showed a comparable pattern to neonatal 
venous plasma [40], we speculate that the increased omega-6/omega-3 
ratio and the decreased omega-3 PUFA levels observed in SGA placentas 
could possibly contribute to the increased risk of cardiometabolic dis-
orders described in later stages of SGA infants’ life. In this sense, lower 
PUFAn3 and higher PUFAn6 levels during pregnancy were associated 
with impaired metabolic status in the offspring at age 6 yr [15,16]. In a 
rat model, high omega-6/omega-3 exposure during perinatal develop-
ment regulates offspring adipogenic potential and conditions adult 
obesity resistance [41]. 
The endogenous fatty acid synthesis is regulated by elongation and 
desaturation enzymes [18]. Our results showed that placentas from SGA 
children had higher D9Dn7 and D5Dn6 activities and lower Elovl5 ac-
tivity. D9Dn7, also known as stearoyol-CoA desaturase-1 (SCD1), cata-
lyzes the desaturation of palmitic acid (C16:0) to its monounsaturated 
counterpart, palmitoleic acid (C16:1). Translational evidence suggests 
that SCD1 plays a pivotal role in regulating lipid and metabolic ho-
meostasis [42]. SCD1 activity has been positively associated with 
obesity, insulin resistance, and dyslipidemia in human and mouse 
models [43–45]. D5Dn6, which is required for the synthesis of LC-PUFA, 
has also been associated with obesity and insulin resistance in children 
[24]. Elovl5 is a condensing enzyme involved in the elongation of a 
broad range of fatty acids including ALA, AA and EPA [46]. It has been 
described as an essential enzyme for hepatic lipid metabolism and the 
deletion of Elovl5 causes hepatic steatosis in mice [47]. Elovl5 has also 
been identified as an epigenetic mark for the risk of type 2 diabetes 
mellitus [48]. Together, these data indicate that placentas from SGA 
infants displayed an altered regulation of fatty acid desaturation and 
elongation activities that have been related to metabolic disturbances in 
several studies. Experimental data showed that enzymatic activity can 
be regulated by omega-3 and omega-6 fatty acids levels [49–51]. We 
propose that the high transfer of maternal dietary omega-6 fatty acids 
across the placenta could inhibit the expression and activity of fatty acid 
desaturases required for the synthesis of long-chain n-3 and n-6 fatty 
acids, leading to fetal growth restriction. An increased desaturase ac-
tivity might benefit the fetus by the achievement and maintenance of 
fetal tissue n-3 and n-6 fatty acid patterns. Fatty acid synthesis/metab-
olism are known to vary in different organs since there is a differential 
demand of individual tissues for specific fatty acids [52]. 
On the basis of these findings, we speculate that the differential fatty 
acid composition noted in SGA placentas could lead to alterations in 
fatty acid transport of essential nutrients to the fetal compartment and 
contribute to the increased cardiometabolic risk described in SGA in-
fants; however, additional longitudinal studies will be necessary to 
address this issue. Moreover, recent data showed that GRP20, an omega- 
3 fatty acid receptor that mediates anti-inflammatory and insulin- 
sensitizing effects [53], is overexpressed in SGA placentas [54]. 
Hence, PUFAn3 and their mediating receptors deserve further attention 
as potential targets of prenatal interventions. 
We acknowledge several limitations in our study. The fatty acid 
profile was not assessed in maternal or fetal blood. The advantage of 
using placenta is that it is a spare tissue at birth available for sample 
collection. Moreover, while the concentration of lipids in blood varies 
according to its local synthesis and influx into the circulation, and its 
absorption from dietary sources and efflux over time; the concentration 
of the lipids in tissues remains more stable [55]. Another concern is that 
while others have studied the fatty acid profile by lipid classes (tri-
glycerides, phospholipids, cholesteryl ester and NEFA) we have studied 
the total lipid content of the placenta. Future studies addressing the lipid 
classes would provide further information on their specific role in the 
placenta. Another limitation is the lack of maternal dietary intake 
questionnaires that would be useful to know whether the low level of 
omega-3 fatty acids present in the SGA placentas is due to a low 
maternal intake and/or dysregulated placental function. Finally, 
because elongase and desaturase activities are difficult to measure, the 
ratios of product-precursor fatty acid pairs were used as a surrogate [56, 
57]. We recognize that apart from the elongase and desaturase activities 
themselves, other factors including maternal diet, maternal metabolism, 
selective placental uptake and selective placental metabolism might 
influence these ratios. The strength of our methodology is that it eases 
the clinical implementation as no previous sorting or isolation would be 
required. 
In conclusion, our data show that placentas of AGA and SGA infants 
differed in fatty acid profile (low omega-3 and high omega-6/omega-3) 
as well as in desaturase and elongase activities (high D9Dn7 and D5Dn6 
and low Elovl5). The omega-3 fatty acid status may represent a modi-
fiable factor related to SGA condition in infants born at term. 
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